Hospitals in US sound alarm on impending chemotherapy shortages
Doctors say it would be ‘national tragedy’ if patients denied life-extending drugs
CONCLUSION: Saline and sterile water irrigation provide an alternative to ICT with equivalent recurrence rate and lower incidence of adverse events. PMID: 30553282 [PubMed - in process]
Le Ngoc Quyen Tran Nanogel-based systems loaded with single anticancer drugs display miscellaneous effectiveness in tumor remission, gradually circumventing mutation and resistance in chemotherapy. Hence, the existence of dual-drug delivered nano-sized systems has been contemporaneous with drug development and preceded the conventional-dose chemotherapy. Among outstanding synergistic drug nanoplatforms, thermosensitive copolymer heparin-Pluronic F127 (Hep-F127) co-delivering cisplatin (CDDP) and curcumins (Cur) (Hep-F127/CDDP/Cur) has emerged as a notable candidate for temperature-responsive drug delivery. The proce...
AbstractBlinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive (Ph+) and Philadelphia chromosome-negative (Ph −) relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL) and B-cell precursor ALL with minimal residual disease. Similarly, initial marketing authorization for blinatumomab in the European Union was granted for the treatment of adults with Ph− R/R B-c...
(Reuters Health) - - Nearly one in 10 cancer patients treated with chemotherapy or newer targeted drugs may be hospitalized for serious kidney injury, a Canadian study suggests.
Brentuximab vedotin (Adcetris, Seattle Genetics) in combination with chemotherapy is significantly more effective than chemotherapy alone in patients with CD30-positive peripheral T-cell lymphomas, according to the multinational phase 3 ECHELON-2 trial.Reuters Health Information
A large pooled analysis of individuals with advanced esophageal cancer showed men and women have different side effects to chemotherapy.
This article reviews the evidence for the putative mechanisms of cancer-related cognitive impairment by examining clinical and preclinical models, primarily those associated with chemotherapy, as well as treatment options and practical clinical advice.
Condition: Gastric, or Gastroesophageal Junction Adenocarcinoma Interventions: Drug: Tislelizumab (BGB-A317) combined with oxaliplatin and capecitabine or Tislelizumab (BGB-A317) combined with Cisplatin and 5-FU; Drug: Placebo combined with oxaliplatin and capecitabine or Placebo combined with Cisplatin and 5-FU Sponsor: BeiGene Not yet recruiting
Conditions: SCLC; PEG-rhG-CSF Intervention: Drug: PEG-rhG-CSF Sponsors: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.; Beijing Cancer Hospital Recruiting
CONCLUSION: Sweet's syndrome is a rare adverse effect of G-CSF. PMID: 30551891 [PubMed - as supplied by publisher]